Abstract: Hydrate inhibitor and corrosion inhibitor composition are disclosed and include from about 10 wt-% to about 99.9 wt-% of an anti-agglomerant low dose hydrate inhibitor (AA-LDHI), wherein the AA-LDHI is a zwitterionic compound or a cationic ammonium compound; from about 0.01 wt-% to about 50 wt-% of a corrosion inhibitor, and at least one additional functional ingredient, solvent, or a combination thereof. Methods for inhibiting corrosion and formation of gas hydrate agglomerants in a fluid are disclosed and include contacting the fluid with a hydrate inhibitor and corrosion inhibitor composition or contacting the fluid with an AA-LDHI, wherein the AA-LDHI is a zwitterionic compound or a cationic ammonium compound, and a corrosion inhibitor, wherein the AA-LDHI and corrosion inhibitor are provided at a weight ratio of about 1:0.001 to about 1:1, and wherein the composition inhibits general and localized corrosion and formation of gas hydrate agglomerants in the fluid.

Abstract: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).

Abstract: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).

Abstract: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).

Abstract: Provided are novel pyrido-pyrimidine derivatives, having the structure of Formula (I): which can be used as anti-inflammatory agents. Also provided are pharmaceutical compositions comprising one or more pyrido-pyrimidine derivatives, as well as methods of treating autoimmune diseases, inflammation or associated pathologies, including for example, sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis, comprising administering such compounds or pharmaceutical compositions comprising them.

Abstract: The present invention relates to novel azabicyclo derivatives as anti-inflammatory agents. The compounds provided herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis. Also provided herein are pharmacological compositions containing compounds provided herein and associated methods of treating sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis, and other inflammatory and/or autoimmune disorders, using the compounds.

Abstract: The present invention relates to novel azabicyclo derivatives of Formula (I) as anti-inflammatory agents which are useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis.

Abstract: The present application relates to a group of novel substituted pentose and hexose monosaccharide derivatives, not previously disclosed, which exhibit potent anti-cell adhesion and anti-inflammatory activities. Methods of preparation, pharmaceutical compositions containing the compounds and methods of treatment, suppression and prevention of cell adhesion mediated chronic inflammatory disorders are also described.